Should I Buy Hims & Hers Health Stock in 2025? Expert Guide for PH Investors

What is Hims & Hers Health?

How much is Hims & Hers Health stock?

The price of Hims & Hers Health stock is rising this week. As of now, the share is trading at $54.83, up by $1.31 (+2.45%) in the last 24 hours and posting a strong 22.25% gain over the past week.

The stock’s P/E ratio stands at 80.63, it pays no dividend (0% yield), and the beta is 2.01, indicating notable price volatility.

Given this rapid growth and elevated volatility, investors in the Philippines should weigh both the dynamic potential and the risks before making a decision.

Our full analysis on Hims & Hers Health stock

Having closely examined Hims & Hers Health’s most recent quarterly results and tracked the stock’s extraordinary multi-year trajectory, our analysis applies both rigor and breadth—factoring in advanced financial indicators, proprietary technical signals, sectoral data, and peer benchmarking. Synthesizing these viewpoints through our in-house evaluation algorithms, we observe a company at the forefront of digital healthcare innovation, with robust momentum and scaling financials. So, why might Hims & Hers Health stock once again become a strategic entry point into the digital health sector in 2025?

Recent Performance and Market Context

Hims & Hers Health (NYSE: HIMS) has delivered a truly remarkable performance across the last twelve months, underscored by a gravity-defying stock increase of over 300% year-on-year, briefly touching $54.83 as of May 27, 2025. Not only has HIMS more than doubled in the past six months, but it also rallied +22.25% just this past week, with daily moves such as the recent +2.45% reflecting accelerating investor conviction.

Several positive catalysts have converged to drive this upward trajectory. Among the most significant is the blockbuster Q1 2025 earnings report, revealing revenue of $586 million—an astonishing +111% year-over-year jump—and net income increasing nearly fivefold to $49.5 million. The company’s subscriber base surged to 2.4 million (+38% YoY), while monthly online revenues per average subscriber soared to $84 (+53%).

The immediate macro and sectoral backdrop is also highly favorable:

• Telehealth Demand: As digitalization in healthcare continues post-pandemic, telemedicine adoption is becoming more entrenched, particularly in the U.S., Hims & Hers Health’s primary market.
• Obesity & Wellness Trends: The explosive growth of the GLP-1 weight-loss drug market, with increasing demand for personalized lifestyle medications and support, fortifies HIMS’ long-term revenue visibility.
• Investor Appetite for Growth: High-growth, tech-oriented U.S. equities remain in strong favor, especially for Philippine investors seeking USD-denominated exposure in rapidly expanding disruptive spaces.

With recent strategic partnerships (notably Novo Nordisk and Eli Lilly) and expansion into new health verticals, HIMS has firmly positioned itself as both a category leader and a top momentum name to monitor in 2025.

Technical Analysis

A deep dive into HIMS’s technical picture reveals a stock in a decisive bullish phase, confirmed by several leading indicators:

• Relative Strength Index (RSI): At 58.48, RSI is neutral—a sign that, despite the rapid ascent, the stock is not overbought and may have considerable runway.
• MACD Momentum: The MACD at 6.49 is steeply positive, confirming the presence of sustainable upward momentum.
• Moving Averages: The share price is comfortably above all major MAs—20-day ($50.71), 50-day ($38.26), 100-day ($37.92), and 200-day ($29.66). This alignment across short- and long-term trends is a classic hallmark of strong bullish structure.
• Support & Resistance: Immediate support zones are identified at $53.35, $51.87, and $50.86. Key resistance levels at $55.84, $56.85, and $58.33 could, if breached, set the stage for continued upside.
• Momentum & Structure: The technical setup is characterized by clean upward breakouts, high-volume confirmation, and resilient price structures—reinforcing the case for a potentially sustained medium-term rally.

In summary, the current technical setup aligns closely with historical precedents for further upside in high-growth tech equities, making entry points near identified support zones particularly attractive.

Fundamental Analysis

Hims & Hers Health is demonstrating operating and financial metrics rarely matched in the broader telehealth sector:

• Explosive Revenue Growth: Q1 2025’s +111% YoY revenue gain stands among the fastest in the digital health space. 2025 full-year guidance targets $2.3–2.4 billion, representing at least 59% growth on an annualized basis.
• Profitability Metrics: Net income of $49.5 million in Q1 (+345% YoY) and adjusted EBITDA growth to $91.1 million evidence that top-line expansion is increasingly translating into tangible profits and robust cash flows.
• Valuation Considerations: While HIMS trades at a premium trailing P/E of 80.63 (forward P/E 56.88), these are justified by rare visibility into prolonged high-double-digit growth. For a category leader in a sector expected to outpace the broader market, multiples remain within reason, particularly when combined with a PEG ratio projected below 1.9 over the next two years.
• Core Strengths:
• Disruptive Model: Direct-to-consumer telehealth, with a proven capability to scale rapidly and efficiently.
• Innovation Pipeline: Aggressive expansion into new specialty care (GLP-1s, weight management, personalized wellness).
• Brand Positioning: Fast-gaining traction as the trusted “front door” for digital healthcare among Millennials and Gen Z.
• Strategic Partnerships: Alliances with big pharma ensure priority access to in-demand drugs, a major edge over competitors.

In sum, HIMS’s growth orientation and structural advantages set it apart within the entire sector, pointing towards continued market share gains and operating leverage as scale grows.

Volume and Liquidity

• Trading Volume: The 10-day average daily volume stands at 51.27 million shares, significantly above earlier periods and sector peers—demonstrating exceptional liquidity and validating the confidence of institutional players.
• Float Structure: The tradable float remains healthy and dynamic, enabling efficient price discovery and accommodating inflows from both retail and global ETF investors. This creates supportive conditions for price appreciation on positive news.

High liquidity is often a magnet for further capital, reinforcing the climate of optimism around HIMS.

Catalysts and Positive Outlook

Multiple tailwinds continue to drive both the near- and long-term prospects for Hims & Hers Health:

• GLP-1 & Weight Management Market: The introduction and scaling up of offerings such as Wegovy, Zepbound, and Mounjaro, combined with bundled follow-up services and meal replacements, dramatically increase ARPU and customer stickiness.
• New Product Launches: Ongoing product innovation—personalization, tracking, and telemedicine tools—fortifies their ecosystem, ensuring differentiation and customer loyalty.
• Strategic Partnerships: Deepening relationships with leading pharmaceutical companies not only increase medication supply reliability but may open up further exclusive distribution opportunities.
• Expansion Plans: With ambitions to launch in new verticals and enter wider geographic markets, HIMS has laid out credible near-term avenues for growth beyond its current core.
• 2030 Long-Term Vision: Management’s target of $6.5 billion in annual revenue and $1.3 billion Adjusted EBITDA by decade-end implies a high-confidence, multi-year growth engine.
• Favorable Sector Context: With global healthcare under pressure to digitalize and consumer demand for accessible, remote care soaring, HIMS stands set to benefit from overarching trends in tech adoption, regulation easing (particularly in telehealth and e-prescriptions), and demographic wellness shifts.

Investment Strategies

Investors considering HIMS can align their approach to their horizons:

• Short-Term: Tactical entries near announced support levels (~$53–$51) provide potential for upside in anticipation of further earnings momentum or positive product announcements. Volatility-induced pullbacks in a high-beta name like HIMS often provide prime accumulation windows.
• Medium-Term: A holding period covering the ensuing two quarters may allow participation in the next earnings releases, further product rollouts, or additional partnership announcements. The technical structure suggests a bullish continuation pattern, with upside targets at and beyond first resistance.
• Long-Term: For those seeking exposure to secular trends in telehealth and digital wellness, HIMS fits strategically into a portfolio aiming to benefit from sustained innovation, margin improvement, and global expansion through 2030. Positioning ahead of further geographic or vertical launches could prove advantageous as the company persists on its growth trajectory.

A careful, phased accumulation approach at, or just above, prevailing support levels can help manage volatility while maximizing upside potential, especially in a dynamic and fast-evolving sector such as digital health.

Is It the Right Time to Buy Hims & Hers Health?

Synthesizing the data, several factors seem to argue convincingly in favor of renewed investment interest for Hims & Hers Health:

• Unmatched Revenue Momentum: Triple-digit revenue and profit growth outpacing almost all digital health peers.
• Validated Model at Scale: Strong and consistent expansion in subscriber base, wallet share, and net income.
• Technical Strength: Clear, sustained bullish momentum confirmed by price action and all major technical indicators.
• Strategic Catalysts: Industry-leading innovation pipeline, partnerships, and ambitious expansion objectives offer many levers for value creation.
• Positive Market Sentiment: High volume, strong liquidity, and ongoing institutional engagement support future re-rating potential.

While any high-growth stock carries risks—valuation and regulatory headwinds most notably—current evidence points to a compelling entry environment. The technical structure presents favorable risk-reward at or near the current price, supported by robust operational momentum and a forward-looking management team.

For investors in the Philippines seeking exposure to high-growth U.S. technology stocks poised to benefit from digital transformation in healthcare, Hims & Hers Health offers a unique blend of scale, innovation, and sector leadership. The company is entering a new bullish phase, with sustained growth drivers and a highly supportive macro backdrop that together seem to represent an excellent opportunity—one worthy of careful consideration for inclusion in growth-focused portfolios.

In summary, Hims & Hers Health stands out as a leader in digital health, combining strong fundamentals with technical momentum and multiple growth catalysts, making the present moment appear particularly favorable for investment consideration.

How to buy Hims & Hers Health stock in the PH?

Buying Hims & Hers Health, Inc. (HIMS) shares online is both simple and secure for Philippine investors when using a regulated online broker. You can choose to invest directly in HIMS shares (“spot buying”) or trade via Contracts for Difference (CFDs), depending on your risk profile and investment goal. Spot buying means you own real shares, while CFD trading allows you to speculate on price movements with added leverage. Each method has its own benefits and costs, which we detail below. For a comprehensive comparison of trusted Philippine brokers and their fees, see the table further down this page.

Cash buying

A cash purchase of Hims & Hers Health shares means you buy the actual stock, becoming a shareholder eligible to benefit directly from changes in the share price. As a retail investor in the Philippines, your broker may charge a fixed commission per trade—typically between ₱250 and ₱500, which is about $5 to $10 USD depending on the platform.

Important Example

Example:
If the HIMS share price is $54.83 (around ₱3,200), you can buy about 18 shares with a $1,000 (approx. ₱58,000) stake, accounting for a brokerage fee of $5.
✔️ Gain scenario:
If the share price rises by 10%, your shares are now worth $1,100.
Result: +$100 gross gain, a +10% return on your investment.

Trading via CFD

CFD trading on Hims & Hers Health shares means you speculate on price movements without owning the actual stock. CFD brokers allow you to magnify your exposure using leverage—often with just a small deposit. Main fees are the “spread” (difference between buy/sell prices) and overnight financing if you hold positions beyond one day.

Important Example

Example:
You open a $1,000 CFD position on HIMS with 5x leverage, giving you $5,000 market exposure.
✔️ Gain scenario:
If the stock price rises by 8%, your leveraged position earns 8% × 5 = 40%.
Result: +$400 gain on a $1,000 deposit (excluding possible spread and overnight fees).

Final advice

Before investing, always compare the fees, commissions, and regulatory protections of different brokers—these can impact your returns, especially depending on your investment size and style. Whether you choose direct share ownership or leveraged CFD trading depends on your risk appetite, goals, and level of experience. Take your time to review our broker comparison below, and choose the method that best aligns with your investment objectives.

Our 7 tips for buying Hims & Hers Health stock

The latest news about Hims & Hers Health

Hims & Hers Health stock surges over 22% this week, supported by exceptional Q1 2025 results and record subscriber growth. The company's stock has experienced robust weekly gains, closing at $54.83 on May 27, 2025, with a 22.25% rise in just one week, outperforming broader indices and indicating strong investor confidence. Key drivers include reported quarterly revenues of $586 million (up 111% YoY), net income of $49.5 million (up from $11.1 million in Q1 2024), and a 2.4 million-strong subscriber base, a 38% annual jump. Filipinos tracking innovative digital health stocks and US-listed growth leaders should note the momentum, especially given the surging popularity of telehealth solutions in both developed and emerging markets.

Hims & Hers Health remains technically bullish, with its share price trading above all major moving averages and reinforced by positive momentum indicators. The Relative Strength Index (RSI) at 58.48 reflects a neutral stance—neither overbought nor oversold—while the MACD at 6.49 confirms an ongoing bullish trend. The stock’s price exceeds the 20-, 50-, 100-, and 200-day moving averages, signaling sustained upward momentum and resilience against recent volatility. For investors and analysts in the Philippines, whose domestic market often mirrors global tech and healthcare sector movements, these technical signals suggest continued strength, offering potential short- and medium-term trading opportunities.

Recent strategic partnerships with Novo Nordisk and Eli Lilly position Hims & Hers Health as a leading provider for the fast-growing weight loss medication market. This week, the firm’s major collaborations have enabled its platform to offer in-demand GLP-1-based therapies, specifically Wegovy, Zepbound, and Mounjaro. Hims & Hers also launched a 6-month offering of Wegovy at $549 per month, aligning with accelerating demand for weight management solutions. With obesity rates on the rise globally and significant local demand in Southeast Asia—including the Philippines—for modern, accessible care options, these partnerships and product expansions bolster growth prospects and underscore Hims & Hers’ competitive differentiation.

The company has reinforced its long-term growth outlook, maintaining guidance for full-year 2025 revenues of $2.3–2.4 billion and ambitious 2030 targets. Hims & Hers projects at least $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030, underscoring management’s confidence in the core telehealth business model and its scalable digital platform. With its direct-to-consumer approach and consistent subscriber growth, the company is positioned to benefit from rising health awareness and digital healthcare adoption in new geographies, a trend increasingly relevant to the Philippine investment community and healthcare sector.

No new regulatory or supply risks have emerged for Hims & Hers Health in the past week, reinforcing the positive market environment for telehealth growth. Despite historic vigilance over telehealth regulations and compounded weight loss drug supply constraints, there have been no adverse developments, allowing the company to operate without immediate headwinds. This regulatory stability supports the ongoing market rally and enhances the stock’s attractiveness for regional investors looking for innovative, high-growth US healthcare equities with global thematic relevance.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.